The global bile duct cancer market is estimated to be valued at US$ 185.4 million in 2023 and is expected to exhibit a CAGR of 12.8% over the forecast period of 2023-2030, as highlighted in… Read More
When it comes to penny stocks, it's important to exercise caution and conduct thorough research. While there are no guarantees, some penny stocks have shown potential for growth. Here is a l… Read More
The FDA announced approval of the Hepzato Kit melphalan injection system as liver-directed therapy for uveal melanoma metastases.
The approval stipulates use in adults with unresectable li… Read More
DelveInsight’s “Cholangiocarcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cholangiocarcinoma, historical a… Read More
Cholangiocarcinoma, also known as bile duct cancer, is spreading widely in Southeast Asia, particularly in the Northeast region of Thailand. High consumption of raw fish in the Asia-Pacific… Read More
NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) — Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of… Read More
Delcath Systems, Inc. (OTCMKTS: DCTH) stock rose 8.81% on September 7th, 2018 and continued its bullish momentum Monday, rising over 14.3% on 10th September, 2018...
The post Why Delcath Sys… Read More
Market Analysis: Global Traveler's Diarrhea Treatment MarketTraveler's diarrhea treatment market is growing at a substantial CAGR of 7.4% in the forecast period of 2020-2027.This rise in mar… Read More
Cholangiocarcinoma, also known as bile duct cancer, is spreading widely in Southeast Asia, particularly in the Northeast region of Thailand. High consumption of raw fish in the Asia-Pacific… Read More
Not long ago, I received a call from an investor relations representative who wanted to know if I’d be interested in hearing about a small biotech company with a drug candidate in Phas… Read More
Zion Market Research has published a new report titled “Bile Duct Cancer Drug Market: by Type (5-fluorouracil (5-FU), Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin, and Others) and… Read More
The company’s lead candidate is tivozanib, which is to treat renal cell carcinoma (RCC), a common type of kidney cancer. The initial symptoms of RCC often include blood in the urine… Read More